<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534842</url>
  </required_header>
  <id_info>
    <org_study_id>SYNB1618-CP-003</org_study_id>
    <nct_id>NCT04534842</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SYNB1618 in Adult Patients With Phenylketonuria</brief_title>
  <acronym>SynPheny-1</acronym>
  <official_title>An Open-label Study of the Efficacy and Safety of SYNB1618 in Patients With Phenylketonuria (SynPheny-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synlogic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synlogic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, single-arm&#xD;
      study of a SYNB1618 dose-ramp regimen. All evaluations and assessments throughout this study&#xD;
      may be conducted either at the clinical site or by a home healthcare professional at an&#xD;
      alternative location (e.g., patient's home, hotel).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-arm Phase 2 study; all participating PKU patients will receive&#xD;
      active study drug, SYNB1618. This study is evaluating a dose-ramp regimen consisting of 4&#xD;
      dose levels of SYNB1618 over 15 days of treatment.&#xD;
&#xD;
      This study has been designed with the flexibility of being able to be conducted either at the&#xD;
      clinical site or by a home healthcare professional at an alternative location (e.g.,&#xD;
      patient's home, hotel).&#xD;
&#xD;
      Patients will be screened for eligibility and complete a customized diet run-in period prior&#xD;
      to starting the 15-day dose ramp ('treatment period'). During the treatment period patients&#xD;
      will be required to adhere to the same customized diet menus as in the diet run-in period.&#xD;
&#xD;
      The efficacy of SYNB1618 will be assessed in this study by measuring the reduction of the&#xD;
      area under the curve (AUC) for plasma D5-phenylalanine (D5-Phe) as well as the reduction of&#xD;
      plasma Phe levels.&#xD;
&#xD;
      Safety will be monitored by documentation of adverse events (AEs), clinical laboratory&#xD;
      measurements, vital signs, and physical examinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in labeled Phe (D5-Phe) in plasma</measure>
    <time_frame>Day 14</time_frame>
    <description>The primary efficacy outcome will be assessed by measuring change from baseline in plasma D5-Phe AUC over 24 hours after D5-Phe administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fasting levels of plasma Phe</measure>
    <time_frame>Day 14</time_frame>
    <description>The secondary efficacy outcome will be assessed by measuring fasting levels of plasma Phe as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 43</time_frame>
    <description>Will be measured by assessing nature and frequency of AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>SYNB1618</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose ramp of SYNB1618</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYNB1618</intervention_name>
    <description>15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618</description>
    <arm_group_label>SYNB1618</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able and willing to voluntarily complete the informed consent process.&#xD;
&#xD;
          3. Diagnosis of classic PKU based on medical history as assessed by the investigator&#xD;
             (e.g., Phe concentration of &gt;1200 µmol/L at any time, low dietary Phe tolerance, or&#xD;
             genetic diagnosis).&#xD;
&#xD;
          4. Blood Phe ≥ 600 µmol/L at Screening.&#xD;
&#xD;
          5. Stable diet including stable medical formula regimen (if used) for at least 1 month&#xD;
             prior to Screening.&#xD;
&#xD;
          6. Available for and agree to all study procedures, including urine and blood collection,&#xD;
             adherence to diet control, follow-up visits, and IMP ingestion compliance.&#xD;
&#xD;
          7. Male patients who are sexually abstinent or surgically sterilized (vasectomy), or&#xD;
             those who are sexually active with a female partner(s) and agree to use an effective&#xD;
             method of contraception (such as condom with spermicide) combined with an acceptable&#xD;
             method of contraception for their non-pregnant female partner(s) (as defined in&#xD;
             Inclusion Criterion #8 below) after informed consent, throughout the study, and for a&#xD;
             minimum of 3 months after the last dose of IMP, and who do not intend to donate sperm&#xD;
             in the period from Screening until 3 months following administration of the IMP.&#xD;
&#xD;
          8. Female patients who meet one of the following criteria:&#xD;
&#xD;
               1. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
                  (human chorionic gonadotropin) at Screening and a negative urine pregnancy test&#xD;
                  at Baseline prior to the start of IMP and must agree to use acceptable method(s)&#xD;
                  of contraception, combined with an acceptable method of contraception for their&#xD;
                  male partner(s) (as defined in Inclusion Criterion #7 above) after informed&#xD;
                  consent, throughout the study, and for a minimum of 3 months after the last dose&#xD;
                  of IMP. Acceptable methods of contraception include hormonal contraception,&#xD;
                  hormonal or non-hormonal intrauterine device, bilateral tubal occlusion, complete&#xD;
                  abstinence, vasectomized partner with documented azoospermia 3 months after&#xD;
                  procedure, diaphragm with spermicide, cervical cap with spermicide, vaginal&#xD;
                  sponge with spermicide, or male or female condom with or without spermicide.&#xD;
&#xD;
               2. Premenopausal woman with one of the following:&#xD;
&#xD;
             i. Documented hysterectomy, ii. Documented bilateral salpingectomy, iii. Documented&#xD;
             bilateral oophorectomy, iv. Documented tubal ligation/occlusion, v. Sexual abstinence&#xD;
             is preferred or usual lifestyle of the patient c. Postmenopausal women (12 months or&#xD;
             more amenorrhea verified by follicle stimulating hormone [FSH] assessment and over 45&#xD;
             years of age, in the absence of other biological or physiological causes).&#xD;
&#xD;
          9. Screening laboratory evaluations (e.g., chemistry panel, complete blood count [CBC]&#xD;
             with differential, urinalysis, creatinine clearance, CRP) within normal limits or&#xD;
             judged to be not clinically significant by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking Kuvan® (sapropterin dihydrochloride) (within 1 week of Screening) or&#xD;
             Palynziq® (pegvaliase-pqpz) (within 1 month of Screening).&#xD;
&#xD;
          2. Inflammatory or irritable bowel disorder of any grade.&#xD;
&#xD;
          3. History of or current immunodeficiency disorder.&#xD;
&#xD;
          4. Intolerance of or allergic reaction to E. coli Nissle or any of the ingredients in&#xD;
             SYNB1618 formulation.&#xD;
&#xD;
          5. Any condition (e.g., celiac disease, gastrectomy, bypass surgery, ileostomy) or&#xD;
             receiving prescription medication or an over-the-counter product that may possibly&#xD;
             affect absorption of medications or nutrients.&#xD;
&#xD;
          6. Currently taking or plans to take any type of systemic (e.g., oral or intravenous)&#xD;
             antibiotic within 28 days prior to the first dose of IMP through final safety&#xD;
             assessment, including planned surgery, hospitalizations, dental procedures, or&#xD;
             interventional studies that are expected to require antibiotics. Exception: topical&#xD;
             antibiotics are allowed.&#xD;
&#xD;
          7. Within the 3 months prior to anticipated first dose, major surgery (an operation upon&#xD;
             an organ within the cranium, chest, abdomen, or pelvic cavity) or inpatient hospital&#xD;
             stay.&#xD;
&#xD;
          8. Dependence on alcohol or drugs of abuse.&#xD;
&#xD;
          9. Administration or ingestion of an investigational drug within the 30 days or 5&#xD;
             half-lives before Screening, whichever is longer, or cell/gene therapy prior to the&#xD;
             Screening visit, or current enrollment in an investigational drug study.&#xD;
&#xD;
         10. Acute or chronic medical, surgical, psychiatric, or social condition or laboratory&#xD;
             abnormality that may increase patient risk associated with study participation,&#xD;
             compromise adherence to study procedures and requirements, or may confound&#xD;
             interpretation of study safety or PD results and, in the judgment of the investigator,&#xD;
             would make the patient inappropriate for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jana Benesh</last_name>
    <phone>(205) 527-8565</phone>
    <email>BeneshJana@prahs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Humphreys</last_name>
    <phone>919-809-3954</phone>
    <email>kristina.humphreys@synlogictx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Murphy</last_name>
      <email>brittany.murphy@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Janet Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen McCune</last_name>
      <phone>352-273-7763</phone>
      <email>hcmccune@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Roberto Zori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bruns</last_name>
      <phone>314-747-5366</phone>
      <email>brunsj@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Grange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Miller</last_name>
      <email>catherine.miller@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>George Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Harding</last_name>
      <phone>503-494-7608</phone>
      <email>hardingc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Cary Harding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Lindenberger</last_name>
      <phone>412-692-7530</phone>
      <email>jessica.lindenberger@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Vockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeeAnna Melton</last_name>
      <phone>615-343-6761</phone>
      <email>leeanna.melton@vumc.org</email>
    </contact>
    <investigator>
      <last_name>John Phillips, III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeoma Ibekwa</last_name>
      <phone>713-500-5064</phone>
      <email>Ifeoma.C.Ibekwe@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hope Northrup</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawn Searle</last_name>
      <phone>801-904-4545</phone>
      <email>searleshawn@prahs.com</email>
    </contact>
    <investigator>
      <last_name>Shawn Searle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Adult Services</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Bailey</last_name>
      <phone>801-587-3605</phone>
      <email>carrie.bailey@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicola Longo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

